Aptose reports safety, CRs, MRD negativity in TUSCANY triplet for newly diagnosed AML

Aptose Biosciences Inc.

Ten newly diagnosed AML patients dosed in TUS+VEN+AZA triplet at 40, 80, 120 mg TUS; no DLTs observed.
At 40 mg, 3 of 4 patients achieved CRs and MRD negativity, including FLT3-ITD, FLT3-WT, and TP53/CK.
At 80 mg, all 3 patients achieved composite CRs (CR/CRi); one TP53-mutated/CK patient had early CRi.
No treatment-related deaths; all 10 subjects remain alive; no prolonged myelosuppression or QT prolongation.
Data presented at EHA 2025; TUS+VEN+AZA well-tolerated with standard of care dosing; enrollment ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.